Literature DB >> 1698743

Effects of fluorouracil and fluorouridine on protein synthesis in rabbit retina.

J A Leon1, J M Britt, R H Hopp, R P Mills, A H Milam.   

Abstract

5-Fluorouracil (5-FU) and its active metabolite 5-fluorouridine (FUR) are currently being evaluated for the treatment of proliferative vitreoretinopathy and the control of scarring after glaucoma filtering procedures. To test for retinal toxicity, the authors examined the effect of intravitreal injections of 5-FU and FUR on protein synthesis in rabbit retinal photoreceptors and ganglion cells. In addition, the toxic effect of subconjunctival 5-FU injections, after a trephine filtering procedure, on ganglion cell protein synthesis was examined. Albino rabbit eyes were given either unilateral intravitreal injections of 1 mg of 5-FU, 2.5 mg of 5-FU, or 0.1 mg of FUR, or subconjunctival injections of 3 mg of 5-FU twice daily after a trephine procedure. Quantitative autoradiography was used to study ganglion cells and photoreceptor outer segment renewal, and scintillation counting was used to quantify newly synthesized protein transported axonally from ganglion cell bodies to the superior colliculus (SC). Marked reduction of labeled protein reaching the SC was noted after either intravitreal 0.1 mg of FUR (41% inhibition after a single injection and 53% after two injections) or 2.5 mg of 5-FU (41% after one injection and 26% after two injections). This reduction was still present after 8 days in eyes receiving 0.1 mg of FUR (32%) and 2.5 mg of 5-FU (22%). Quantitative autoradiography of retinal photoreceptors and ganglion cells corroborated these data, demonstrating inhibition of outer segment renewal after one or two injections of either 0.1 mg of FUR or 2.5 mg of 5-FU. This inhibitory effect was statistically significant using the paired t-test for both drugs. No mean inhibition was observed after intravitreal 1 mg of 5-FU injections or after subconjunctival injections of 5-FU.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698743

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Intravitreal crystalline drug delivery for intraocular proliferation diseases.

Authors:  Lingyun Cheng; Karl Hostetler; Nadya Valiaeva; Ajay Tammewar; William R Freeman; James Beadle; Dirk-Uwe Bartsch; Kathy Aldern; Iryna Falkenstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-20       Impact factor: 4.799

2.  A study of toxicity of 5-fluorouracil on bovine trabecular meshwork cells in vitro.

Authors:  F Jiang; H Wei; Y Lu
Journal:  J Tongji Med Univ       Date:  2001

3.  The architectural transcription factor high mobility group I(Y) participates in photoreceptor-specific gene expression.

Authors:  K Y Chau; N Munshi; A Keane-Myers; K W Cheung-Chau; A K Tai; G Manfioletti; C K Dorey; D Thanos; D J Zack; S J Ono
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

4.  Growth inhibition of human Tenon's capsule fibroblasts and rabbit dermal fibroblasts with non-carcinogenic N-alkylated anthracyclines.

Authors:  U H Steinhorst; E P Chen; S F Freedman; R Machemer; D L Hatchell
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-06       Impact factor: 3.117

5.  Antiproliferative property of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine (HDP-PMEG) for unwanted ocular proliferation.

Authors:  Jiangping Hou; Yuli Li; Zhonglou Zhou; Nadejda Valiaeva; James R Beadle; Karl Hostetler; William R Freeman; Dan-Ning Hu; Hao Chen; Lingyun Cheng
Journal:  Mol Vis       Date:  2011-03-02       Impact factor: 2.367

6.  Changes in macular thickness after trabeculectomy with or without adjunctive 5-fluorouracil.

Authors:  Aistė Kadziauskienė; Ernesta Strelkauskaitė; Eglė Mockevičiūtė; Rimvydas Ašoklis; Eugenijus Lesinskas; Leopold Schmetterer
Journal:  Acta Med Litu       Date:  2017
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.